Q3 2024 Bioatla Inc Earnings Call Transcript
Key Points
- BioAtla Inc (BCAB) reported promising clinical trial results for its drug candidate, Tab war 2 80 C Zy A THEIN, showing a total of 11 responses out of 29 evaluable patients with refractory head and neck cancer.
- The drug candidate received fast track designation from the FDA, highlighting its potential in addressing unmet medical needs.
- BioAtla Inc (BCAB) observed a median overall survival of approximately nine months in heavily pretreated head and neck cancer patients, which is competitive compared to current standard treatments.
- The company received supportive feedback from the FDA for its proposed pivotal trial design, potentially leading to accelerated marketing authorization.
- BioAtla Inc (BCAB) reported a significant decrease in research and development expenses, reflecting efficient prioritization of clinical programs and completion of preclinical development for certain assets.
- BioAtla Inc (BCAB) reported a net loss of $10.6 million for the quarter, despite recognizing $11 million in collaboration revenue.
- The company's cash and cash equivalents decreased significantly from $111.5 million at the end of 2023 to $56.5 million as of September 30, 2024.
- There is uncertainty regarding the sufficiency of cash to fund operations beyond early 2026, despite current projections.
- The company is still in the process of determining the most efficient path for a future pivotal trial for its cab actual A DC asset MBOM, indicating potential delays.
- BioAtla Inc (BCAB) is engaged in ongoing discussions for collaborations, which may impact timelines and resource allocation for its phase two assets.
Good day, everyone and welcome to today's Bioatla third-quarter, 2024 earnings call. (Operator Instructions)
It is now my pleasure to turn the conference over to Bruce Mackle of LifeSci advisors.
Thank you operator and good afternoon. Everyone with me today on the phone from Bio Atla are Dr. Jay Short, Chairman CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following today's call, Dr. Eric Sievers, Chief Medical Officer; and Sherry Lydick, Chief Commercial Officer will join Jay and Rick in a short Q&A earlier this afternoon,
Bio Atla released financial results and a business update for the third quarter ended September 30 2024. A copy of the press release and corporate presentation are available on the company's website before we begin. I'd like to remind everyone that statements made during this conference call will include forward-looking statements including but not limited to statements regarding Bio Atlas business plans and prospects and whether it's clinical trials
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
